Lung Cancer
Antiracism intervention reduces disparities in timely lung cancer surgery
The racial gap in timely surgery between Black and white patients with early-stage lung cancer improved after an antiracism intervention, according to study results published in Journal of Clinical Oncology.
Black patients with cancer have worse COVID-19 outcomes
Black patients with cancer had worse COVID-19 outcomes than white patients, according to results of a retrospective cohort study published in JAMA Network Open.
FDA rejects sintilimab with chemotherapy for non-small cell lung cancer
Cancer programs aim to address critical gaps in screening due to pandemic
Cancer screening remains in need of urgent attention, and online resources may help facilities close gaps and address screenings missed in 2020, according to a prospective quality improvement study published in Cancer.
AccessHope aims to provide ‘best care close to home’ for people with cancer
H. Jack West, MD, medical oncologist at City of Hope, spoke with Healio about AccessHope.
Adjuvant pembrolizumab extends DFS in resected early-stage non-small cell lung cancer
Pembrolizumab significantly extended DFS among patients with completely resected stage IB to stage III non-small cell lung cancer, irrespective of PD-L1 expression, according to a study presented during an ESMO Virtual Plenary session.
Updated lung cancer screening guidance broadens eligibility, but challenges remain
Healio spoke with Peter J. Mazzone, MD, MPH, director of the Lung Cancer Program and Lung Cancer Screening Program at the Cleveland Clinic Cancer Center Respiratory Institute, about how the 2021 changes to the USPSTF lung cancer screening guidelines have affected the number of patients being screened, improvements in patient outcomes and how specialists should continue to prepare for the effects of the updated guidelines.
FDA approves FoundationOne CDx to guide treatment for non-small cell lung cancer subset
The FDA approved FoundationOne CDx as a companion diagnostic to guide treatment selection for certain patients with non-small cell lung cancer.
Toripalimab plus initial chemotherapy prolongs PFS, OS in non-small cell lung cancer
The addition of toripalimab to first-line chemotherapy prolonged PFS and OS among patients with advanced non-small cell lung cancer without EGFR/ALK mutations, according to study results.
Age at diagnosis and cancer subtype may affect risk for CV death among cancer survivors
Among survivors of nine common cancers, risk for CV death overtook cancer mortality for most cancer subtypes among patients aged at least 80 years, researchers reported.